Author: Pettit, Natasha N; Pisano, Jennifer; Nguyen, Cynthia T; Lew, Alison K; Hazra, Aniruddha; Sherer, Renslow; Mullane, Kathleen
Title: Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk? Cord-id: apg79103 Document date: 2020_12_14
ID: apg79103
Snippet: INTRODUCTION: Remdesivir (RDV) is FDA approved for COVID-19, but not recommended for patients with severe renal impairment (SRI, i.e. creatinine clearance < 30ml/min). Few studies have evaluated RDV in patients with SRI due to theoretical toxicity concerns. METHODS: Hospitalized patients receiving RDV for COVID-19 between 5/1/2020-10/31/2020 were analyzed in a retrospective chart review. We compared incident adverse events (AEs) following RDV in patients with and without SRI, including hepatotox
Document: INTRODUCTION: Remdesivir (RDV) is FDA approved for COVID-19, but not recommended for patients with severe renal impairment (SRI, i.e. creatinine clearance < 30ml/min). Few studies have evaluated RDV in patients with SRI due to theoretical toxicity concerns. METHODS: Hospitalized patients receiving RDV for COVID-19 between 5/1/2020-10/31/2020 were analyzed in a retrospective chart review. We compared incident adverse events (AEs) following RDV in patients with and without SRI, including hepatotoxicity, nephrotoxicity, any reported AE, mortality and length of stay. RESULTS: A total of 135 patients received RDV, 20 patients had SRI. Patients with SRI were significantly older (70 vs. 54 years, p=0.0001). The incidence of possible AEs following RDV was 20% among those with SRI versus 11% without (p=0.26). LFT elevations occurred in 10% vs. 4% (p=0.28), and SCr elevations occurred in 20% vs. 6% (p=0.06) of patients with SRI versus those without, respectively. The LFT and SCr elevations were not attributed to RDV in either group. Mortality and length of stay were comparable and consistent with historical controls. CONCLUSION: RDV AEs occurred infrequently with low severity and were not significantly different between those with and without SRI. While a higher percentage of patients with SRI experienced SCr elevations, 3 (75%) patients were in AKI prior to RDV. Overall, the use of RDV in this small series of patients with SRI appeared to be relatively safe, and the potential benefit outweighed the theoretical risk of liver or renal toxicity; however, additional studies are needed to confirm this finding.
Search related documents:
Co phrase search for related documents- acute aki kidney injury and admission date: 1
- acute aki kidney injury and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute aki kidney injury and liver function: 1, 2, 3
- acute aki kidney injury and liver inflammation: 1, 2, 3, 4
- acute aki kidney injury and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute liver injury and admission day: 1, 2, 3, 4, 5
- acute liver injury and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute liver injury and liver function test: 1
- acute liver injury and liver inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute liver injury and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute liver injury and liver necrosis: 1, 2
- additional benefit and admission day: 1
- additional benefit and liver injury: 1
- admission day and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- admission day and liver function test: 1, 2
- admission day and liver inflammation: 1
- admission day and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- admission day and liver necrosis: 1
Co phrase search for related documents, hyperlinks ordered by date